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Abstract
AIM: To develop an improved p38 MAPK inhibitor-based 
serum-free medium for embryoid body cardiomyocyte 
differentiation of human pluripotent stem cells.
METHODS: Human embryonic stem cells (hESC) dif-
ferentiated to cardiomyocytes (CM) using a p38 MAPK 
inhibitor (SB203580) based serum-free medium (SB 
media). Nutrient supplements known to increase cell 
viability were added to SB medium. The ability of these 
supplements to improve cardiomyogenesis was evalu-
ated by measurements of cell viability, total cell count, 
and the expression of cardiac markers via  flow cytom-
etry. An improved medium containing Soy hydrolysate 
(HySoy) and bovine serum albumin (BSA) (SupSB me-
dia) was developed and tested on 2 additional cell lines 
(H1 and Siu-hiPSC). Characterization of the cardiomyo-
cytes was done by immunohistochemistry, electrophysi-
ology and quantitative real-time reverse transcription-
polymerase chain reaction. 
RESULTS: hESC cell line, HES-3, differentiating in SB 
medium for 16 d resulted in a cardiomyocyte yield of 
0.07 ± 0.03 CM/hESC. A new medium (SupSB media) 
was developed with the addition of HySoy and BSA to 
SB medium. This medium resulted in 2.6 fold increase 
in cardiomyocyte yield (0.21 ± 0.08 CM/hESC). The ro-
bustness of SupSB medium was further demonstrated 
using two additional pluripotent cell lines (H1, hESC 
and Siu1, hiPSC), showing a 15 and 9 fold increase in 
cardiomyocyte yield respectively. The age (passage 
number) of the pluripotent cells did not affect the car-
diomyocyte yields. Embryoid body (EB) cardiomyocytes 
formed in SupSB medium expressed canonical cardiac 
markers (sarcomeric α-actinin, myosin heavy chain and 
troponin-T) and demonstrated all three major pheno-
types: nodal-, atrial- and ventricular-like. Electrophysi-
ological characteristics (maximum diastolic potentials 
and action potential durations) of cardiomyocytes de-
rived from SB and SupSB media were similar.
CONCLUSION: The nutrient supplementation (HySoy 
and BSA) leads to increase in cell viability, cell yield and 
cardiac marker expression during cardiomyocyte dif-
ferentiation, translating to an overall increase in cardio-
myocyte yield.
© 2013 Baishideng. All rights reserved.
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Core tip: Nutrient supplements were screened for im-
proving cell survival during the cardiomyocyte differen-
tiation process of human embryonic stem cells (hESC) 
and human induced pluripotent stem cells (hiPSC) in 
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a serum-free medium based on the inhibition of p38 
MAPK (SB media). Soy hydrolysate and bovine serum 
albumin supplementation was found to improve cell 
viability and therefore increased the yield of HES-3 
cardiomyocytes by 2.6-fold over non-supplemented 
SB medium. The enhancing effect of this medium was 
demonstrated in an additional hESC line (H1) and Siu1-
hiPSC cell line (15 and 9 fold respectively). The cardio-
myocytes formed expressed canonical cardiac markers 
(sarcomeric α-actinin, myosin heavy chain and tropo-
nin-T) and demonstrated all three major phenotypes: 
nodal-, atrial- and ventricular-like.
Ting S, Lecina M, Chan YC, Tse HF, Reuveny S, Oh SKW. 
Nutrient supplemented serum-free medium increases cardio-
myogenesis efficiency of human pluripotent stem cells. World J 
Stem Cells 2013; 5(3): 86-97  Available from: URL: http://www.
wjgnet.com/1948-0210/full/v5/i3/86.htm  DOI: http://dx.doi.
org/10.4252/wjsc.v5.i3.86
INTRODUCTION
Heart disease is one of  the most common causes of  mortal-
ity in the world and accounts for more than 800000 deaths 
per year on average in the United States alone[1]. After an epi-
sode of  major cardiac insult (such as a myocardial infarction), 
the heart can lose up to 2 billion cardiomyocytes. Being an 
organ that cannot auto-regenerate, progressive heart failure 
develops. Cardiomyocyte cell therapy can thus be a potential 
cure for heart failure after myocardial infarction, and it is sug-
gested that at least one billion cardiomyocytes will be required 
per patient for such treatment[2]. 
Human embryonic stem cells (hESCs) present an 
attractive cell source for generating large amounts of  
cardiomyocytes, due to their pluripotency and ability to 
proliferate for multiple passages[3]. Several studies have 
reported techniques to efficiently differentiate hESCs to 
cardiomyocytes via growth factors and small molecule 
inhibitors[4-8]. Current cardiomyocyte differentiation 
protocols can be divided into two groups: differentiat-
ing hESC in 2D monolayers culture or in 3D suspended 
embryoid bodies (EBs) cultures[9]. Although monolayer 
differentiation protocols have achieved high yields of  
cardiomyocytes[6,10], the scalability of  these methods is 
problematic and they have limited capability in generating 
the amounts of  cardiomyocytes needed for cell therapy. 
On the other hand, methods that involve EBs formation, 
which have better potential for scale up, have lower yields 
of  cardiomyocyte, and requires extensive use of  expen-
sive growth factors like BMP4 and activin A at multiple 
specific time points during differentiation[7,11-13]. In addi-
tion, the growth factors have to be optimized for differ-
ent cell lines, growth platforms or passage numbers[14,15]. 
As such, there is a lack of  protocols for cardiomyocyte 
differentiation in EB suspended cultures that are cost-ef-
fective, scalable and most importantly robust. Previously, 
we have developed a simple scalable methodology to dif-
ferentiate hESCs to cardiomyocytes using a serum-free 
differentiation medium[16,17] containing a small molecule 
p38 MAP kinase inhibitor SB203580 (SB media)[18,19]. The 
enhancing effect of  SB203580 on cardiomyogenesis of  
hESC has been correlated to the expected inhibition of  
the p38 pathway as well as the activation of  JNK[20]. This 
suggests a regulatory interlink between the JNK and p38 
pathways during cardiomyogenesis. Compared to pro-
tocols based on growth factors, small molecules are less 
costly and more amenable for good manufacturing prac-
tice (GMP) manufacturing of  cells[21]. However, the SB 
medium is essentially protein-free and lacks nutrients (e.g., 
lipids) and growth factors. From the low cell viability and 
yield observed, we hypothesized that SB medium has nu-
tritional deficiencies that limit cardiomyogensis, especially 
in the initial stages of  the differentiation process. 
In this study, we sought to improve the survival of  cells 
in SB medium and thereby enhance cardiomyogenesis us-
ing the embryoid body method of  differentiation. For suc-
cessful growth and maintenance of  metabolic functions of  
differentiated human cells in vitro, appropriate culture condi-
tions are required to mimic the physiological conditions in 
vivo[22,23]. The culture medium is one of  the most important 
factors in maintaining cell and tissue culture as it provides 
nutrients and salts, hormones and growth factors, buffering 
elements and oxygen supply[22-24]. While media supplements 
have been developed for a variety of  cell types, none have 
been performed for stem cell differentiation. 
In this study, nutritional components were screened 
for an improvement in overall yields of  cardiomyocytes 
of  HES-3 cells using serum-free and insulin-free SB me-
dium. Two supplements, Soy-hydrolysate (HySoy) and 
bovine serum albumin (BSA), resulted in improved car-
diomyocyte differentiation efficiency. The concentrations 
of  both supplements were optimized, resulting in an in-
crease in cell growth and differentiation. The robustness 
of  this new medium (SupSB media) was evaluated using 
the H1 and HES-3 hESC, as well as the Siu1-hiPSC cell 
lines (2.6 to 15.0 fold increase in cardiomyocyte yield). 
Similar cell yields and differentiation efficiency were 
obtained using 9 different batches of  BSA and HySoy 
indicating that batch variability is not a major concern. 
Cardiomyocytes formed in SupSB media expressed ca-
nonical cardiac markers and electrophysiological studies 
demonstrated successful cardiac differentiation to give all 
the three major phenotypes of  cardiomyocytes: nodal-, 
atrial- and ventricular-like. In summary, we have devel-
oped a cost-effective, scalable and robust protocol for 
cardiomyocyte differentiation by improving the p38 MAP 
kinase protocol with the addition of  BSA and HySoy. 
SupSB media increases cell yield and cardiac expression 
markers during cardiomyocyte differentiation, translating 
to an overall increase in cardiomyocyte yield.
MATERIALS AND METHODS
Culture of hESCs and hiPSCs
HES-3 [(46, XX); ES Cell International], H1 [(46, XY); 
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WiCell], and Siu1-hiPSC (Professor Tse HF, The Univer-
sity of  Hong Kong) with normal karyotypes were cultured 
in KNOCKOUT medium on inactivated immortalized 
mouse feeders. The medium was refreshed daily and the 
cells were passaged weekly. Cultures were kept at 37 ˚C 
with 5% CO2.
Differentiation to cardiomyocytes
hESC cultures were washed using phosphate buffered 
saline (PBS) (Invitrogen), cut into small clumps (EZ-
passage tool; Invitrogen), and seeded at 1.33  ×  106 cells/
mL in ultra-low attachment 12-well plates (Nunc). The 
plates were agitated for 1 h and then cultured in static 
conditions at 37˚C in a humidified atmosphere with 5% 
CO2. The differentiation medium (SB media) comprised 
Dulbecco’s modified Eagle’s medium (Invitrogen) supple-
mented with 2 mmol/L L-glutamine (Invitrogen), 0.182 
mmol/L sodium pyruvate (Invitrogen), 1% nonessential 
amino acids (Invitrogen), 0.1 mmol/L 2-mercaptoethanol, 
5.6 mg/L transferrin (Invitrogen), and 20 mg/L sodium 
selenite (Sigma). A solution of  5 mmol/L of  p38-MAPK 
inhibitor (SB203580; Sigma), dissolved in dimethylsulfox-
ide (Sigma), was added to the medium at a final concen-
tration of  5 µmol/L. The medium was refreshed every 2 
d following the previously described protocol[16]. 
Supplements for cardiomyocyte differentiation
Various supplements (Table 1) were added to the SB 
medium and tested for cell yields and cardiomyogenesis 
efficiency using the above differentiation protocol.  
Cardiomyocytes harvesting and quantification
Following the protocol established by Lecina et al[15] and 
Ting et al[16], beating aggregates collected from 1 well 
were washed with 5 mL of  PBS without Ca2/ Mg2 (PBS-) 
(Invitrogen), and incubated for 30 mins in 500 µL PBS- 
solution containing 1.6 mg/mL collagenase (Sigma) and 
20% fetal bovine serum (Hyclone). Thereafter, 500 µL of  
0.25% trypsin EDTA (Invitrogen) was added to gener-
ate single-cell suspensions. Cell suspensions were finally 
filtered through a 40-µm cell strainer (Becton Dickinson), 
fixed, and permeabilized (Caltag Laboratories). For FACS 
analysis, cells were incubated with anti-myosin heavy 
chain (anti-MHC; MF20, dilution 1:200; Developmen-
tal Studies Hybridoma Bank), anti-sarcomeric α-actinin 
(anti-SA; 1:100; Sigma) and anti-Troponin T (anti-cTnT; 
1:200; Thermo Scientific). Fluorescein isothiocyanate-
conjugated antimouse antibody (1:500; DAKO) was used 
as a secondary antibody. Dot plots for both anti-MHC 
and anti-SA are shown in Figure 1. All incubations were 
carried out at room temperature for 30 min. FACS mea-
surements were done using Guava (Millipore). 
Cell counting and calculations of cardiomyocyte/hESC 
yield and normalized yield
Cell concentration was determined by the nuclei count 
method using NucleoCounter (Chemometec). Apopto-
sis and cell proliferation were evaluated using Annexin 
V (Invitrogen) and Ki-67 (BD Biosciences) respectively 
via FACS. Cardiomyocyte yields were calculated fol-
lowing published protocols[16,17], namely: CM hESC 
iield = (cell countDay 16/cell countDay 0: Initial hESC seeded) × (% 
positive cellsMHC, SA/100); normalised yield = (CM/hESC 
yieldCondition)/(CM/hESC yieldControl).
qRT PCR
Total RNA was isolated from the cells (< 5 × 106) using 
RNeasy Mini Kit (Qiagen) following the supplier’s proto-
col. Reverse transcription was carried out with 1 µg total 
RNA using SuperScript Ⅲ (Invitrogen). Real-time PCR 
was performed by applying a standard two-step amplifi-
cation protocol on an ABI 7500 system (Applied Biosys-
tem) to detect mRNA expression. Normalization of  the 
results was done using a house-keeping gene, GAPDH. 
Primer sequences for Nanog, OCT 4, T-bra, Mesp 1, 
Nkx 2.5, MHC and GAPDH are provided in Table 2.
Immunocytochemistry
Cell aggregates were harvested, washed with PBS-, me-
chanically dissociated by pipetting, and plated in 24-well 
plates for 2 d in the SupSB medium at 37˚C in a hu-
midified atmosphere with 5% CO2. The cells were then 
washed twice with PBS- and fixed with 4% paraformal-
dehyde (2 mL for 20 minutes at room temperature). After 
washing twice with PBS-, permeabilization and blocking 
was done using 0.1% Triton X-100 and 10% goat serum 
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heavy chain and anti-sarcomeric 
α-actinin of HES-3 differentiated 
cardiomyocytes. A: Myosin heavy 
chain (MHC); B: Sarcomeric α-actinin 
(SA). 
respectively. The following antibodies were used: anti-
MHC (MF20; Developmental Studies Hybridoma Bank), 
anti-SA (Sigma), and anti-troponin-T (Thermo Scientific). 
Nuclear staining was done using SlowFade Glow with 
DAPI (4’6-diamidino-2-phenylindole) (Invitrogen). The 
fluorescence was observed using an Olympus IX71 fluo-
rescence microscope (Olympus) coupled with Olympus 
imaging software Cell P.
Electrophysiology
Standard whole-cell patch-clamp recordings were per-
formed at 37 ± 0.5 ℃ to record the action potential phe-
notypes (HEKA Instruments Inc. Southboro, MA, United 
States) of  beating cardiomyocyte aggregates as previously 
described[25,26] . Patch pipettes were prepared from 1.5-mm 
thin-walled borosilicate glass tubes using a Sutter micro-
pipette puller P-97 and had typical resistances of  3-4 MΩ 
when filled with an internal solution containing (mmol/L): 
110 K+ aspartate, 20 KCl, 1 MgCl2, 0.1 Na-GTP, 5 Mg-
ATP, 5 Na2-phosphocreatine, 5 EGTA, 10 HEPES, and 
pH adjusted to 7.3 with KOH. The external Tyrode’s 
bath solution consisted of  (mmol/L): 140 NaCl, 5 KCl, 
1 MgCl2, 0.4 KH2PO4, 1.8 CaCl2, 10 Glucose, 5 HEPES, 
with pH adjusted to 7.4 with NaOH. Twenty consecutive 
action potentials from spontaneously firing HES3-derived 
cardiomyocytes were recorded per cell to ensure stable 
waveforms for analysis. For the electrically quiescent 
cardiomyocytes, a stimulation of  0.1-1 nA for 5 ms was 
given to elicit an action potential. The sampling frequency 
was 2.00 kHz and data were corrected for the liquid junc-
tion potentials of  +15.9 mV. Maximal diastolic potential 
as well as action potential duration at 90% (APD90) and 
50% repolarization level (APD50) were measured.
Statistical analysis
Experiments were done using three independent repli-
cates. The significance of  the results was calculated by 
Student’s t-test or by one-way ANOVA (P < 0.05, P < 
0.01).
RESULTS
Identifying nutritional supplements that can improve 
cardiomyocyte differentiation
In order to identify elements that can increase cardiomyo-
cyte differentiation, we selected a panel of  defined and 
non-defined nutritional supplements (Table 1) which are 
known to support cell growth of  a variety of  cell lines[27]. 
The supplements were used at concentrations typically 
reported for animal cell culture. 
HES-3 cells were seeded at a concentration of  1.33 
× 106 cells/mL and differentiated in SB medium supple-
mented with the various supplements described in Table 1. 
Control cultures were differentiated in non-supplemented 
SB medium. After 16 d, cells were harvested and mea-
sured for cell yield and expression of  the cardiac mark-
ers sarcomeric α-actinin (SA) and myosin heavy chain 
(MHC). A third antibody, cTnT which detects cardiac 
troponin was also used to verify the results (data not 
shown). The differentiation efficiency of  the supplement 
was evaluated by dividing the yields of  cardiomyocytes 
produced per seeded hESC in the supplemented culture 
with the one in the control culture (normalized cardio-
myocyte yield). This parameter considers both the dif-
ferentiation efficiency (percentage of  cardiomyocytes) 
and final number of  total cells, making it meaningful for 
process analysis and evaluation[16,17].
The nutritional supplements did not significantly af-
fect cell counts. However, supplementing the media with 
BSA and HySoy improved the metabolic state of  the 
cells, leading to an increase in normalized cardiomyocyte 
yield with improvements of  1.47 ± 0.20 and 2.45 ± 0.33, 
fold on average respectively, compared to the control 
(Figure 2). Addition of  vitamins had no effect on the 
differentiation process. Yeastolate, Yeast extract, and Vi-
tamin E reduced cardiomyocyte yields showing a negative 
effect on cardiac marker expression (data not shown), 
while cholesterol had a negative effect on cell yields. 
In order to further increase cardiomyocyte yields, the 
effect of  HySoy and BSA concentration on cardiomyo-
cyte yield was further investigated (Figure 3). At a BSA 
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Table 1  List of nutritional supplements
Supplements Concentration/addition Source
MEM vitamin solution (× 100) 30 µL/mL Gibco 11120
Yeastolate ultrafiltrate (× 50) 20 µL/mL Gibco 18200
Vitamin E 70 µg/mL Sigma T3376
Synthechol (cholesterol) (× 500) 12 µL/mL Sigma S5442
Yeast extract 50 µg/mL Sigma Y1625
Bovine serum albumin 50 µg/mL Gibco A10008-01
Soy hydrolysate 50 µg/mL Kerry Bio-science 
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Figure 2  Effect of nutritional supplements added to SB medium on HES-3 
differentiation to cardiomyocytes. Differentiation efficiency is based on two 
FACS markers: myosin heavy chain (MHC) and sarcomeric α-actinin (SA). Cell 
and cardiomyocyte (CM) yields were measured at day 16 of culture. Results were 
normalized against the yields obtained in SB medium (control). (n = 3, aP < 0.05, 
bP < 0.01 vs cell yield). BSA: Bovine serum albumin; HySoy: Soy-hydrolysate.
a
b
concentration of  0.5% v/v, an increase in cell growth 
compared to the control was observed, achieving an 
average of  2.54 × 106 cells/mL (Figure 3A). Similarly, 
cultures supplemented with 0.25% w/v HySoy achieved 
a maximum cell density of  2.51 × 106 cells/mL. The 
supplements also improved cell viability, showing > 85% 
viability as compared to 65% in the controls (SB media). 
This increase in cell growth and viability resulted in a 
2-fold increase in normalized cardiomyocyte yield for 
both BSA and HySoy (Figure 3C). Although there was no 
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Table 2  Quantitative real-time reverse transcription-polymerase chain reaction primers
Primers for qPCR Forward (5’→3’) Reverse (5’→3’) 
Nanog GAAAAACAACTGGCCGAAGAAT GGTGCTGAGGCCTTCTGC
4-Oct AACGACCATCTGCCGCTTT GGCCGCAGCTTACACATGTT
T-bra AATTTGGTCCAGCCTTGGAAT CGTTGCTCACAGACCACAG
Mesp 1 GACGTGCTGGCTCTGTTG TGTCACTTGGGCTCCTCAG
Nkx 2.5 CAAGTGTGCGTCTGCCTTT TTGTCCGCCTCTGTCTTCTC
MHC ATTGCTGAAACCGAGAATGG CGCTCCTTGAGGTTGAAAAG
GAPDH GTCGGAGTCAACGGATTTGG AAAAGCAGCCCTGGTGACC
qPCR: Quantitative polymerase chain reaction; MHC: Myosin heavy chain; GAPDH: Glyceraldehyde 
3-phosphate dehydrogenase.
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Figure 3  Additive and dose effect of Soy hydrolysate and bovine serum albumin supplementation on HES-3 differentiation to cardiomyocytes. HES-3 cells 
differentiated in SB medium containing varying concentrations of bovine serum albumin (BSA) and Soy hydrolysate (HySoy), as well as a combination of both supple-
ments (SupSB media), were harvested on day 16 and evaluated for total cell count (A) and cardiac specific markers, myosin heavy chain (MHC) and sarcomeric α-actinin 
(SA) (B); C: The results were summarized by calculating the normalized yield which takes into account the ratio of cardiomyocyte at day 16 compared to the initial hu-
man embryonic stem cell seeded. Normalized yields are based on both MHC and SA markers. Dot plots of both MHC and SA are shown in Figure 1. (n = 4. bP < 0.01 
vs SB medium; cP < 0.05; dP < 0.01 vs SupSB media). 
statistical difference in the level of  expression of  cardiac 
markers (SA and MHC) between the cultures supple-
mented with different concentrations of  BSA and HySoy 
as compared to the control, a general trend of  increased 
level of  expression was observed in cultures supplement-
ed with 0.25% w/v HySoy and 0.5% v/v BSA (Figure 
3B). Embryoid bodies of  all cultures started beating at 
day 9, indicating that the supplements did not affect the 
process of  cardiac differentiation temporally. 
Additive effect of HySoy and BSA supplements further 
increases cardiomyocyte yields 
Next, we explored the effects of  combining both supple-
ments on cell yield and cardiac marker expression (SA 
and MHC). HES-3 cells were seeded in medium contain-
ing both 0.25% w/v HySoy and 0.5% v/v BSA (SupSB 
media) and compared to control cultures supplemented 
by HySoy and BSA alone or not supplemented at all. 
Results show a further increase in normalized car-
diomyocyte yield (2.6-fold) when HySoy and BSA were 
combined, compared to only a 2-fold increase with the 
individual supplements alone (P < 0.01) (Figure 3C). This 
increase in cardiomyocyte yield can be attributed to a 
higher percentage of  differentiated cardiomyocytes as in-
dicated by a higher percentage of  MHC-expressing cells 
(16.5% of  cells) cultured in the SupSB medium vs. the 
individual supplements (10%-12%) (Figure 3B). In addi-
tion, there was also an increase in cell yield of  cultures in 
SupSB media resulting in 2.79 × 106 cells/mL (Figures 3A 
and Figure 4), that was statistically significant (P < 0.01). 
The variability between different batches of  BSA and Hy-
Soy were also tested. Differentiation experiments using 9 
different batches of  BSA and HySoy were conducted and 
little variability was observed. A high level of  apoptotic 
cells (60% of  total cells), measured by annexin V, was 
observed during the first day of  differentiation, which 
correlates to cell death probably as a result of  mechanical 
manipulation of  the culture during seeding. Thereafter, 
gradual increase in cell yields and down regulation of  
apoptotic markers were observed (Figure 4). In summary, 
the additive effect of  HySoy and BSA increased cardio-
myocyte yield further over individual supplements alone, 
through increasing cell yield and expression of  cardiac 
markers.
Kinetics of cell growth and marker expression during 
HES-3 differentiation
Next, we investigated the underlying factors that resulted 
in the overall increase in cardiomyocyte yields using the 
optimal concentrations of  both supplements. Differen-
tiating HES-3 cultures supplemented with optimal con-
centrations of  HySoy and BSA were monitored for 10-16 
d. Every 2-3 d cells were harvested and analyzed for cell 
yield, expression of  pluripotent markers (Nanog and 
OCT4), mesoderm markers (Mesp 1 and T-bra), the early 
cardiac marker Nkx 2.5 and the late cardiac marker MHC 
via qRT-PCR (Figure 5). 
More than 30% of  cell death was observed during the 
first day in both the supplemented as well as the control 
cultures. This phenomenon can be attributed to the me-
chanical cutting of  the HES-3 cultures and the adapta-
tion of  the cells to the new differentiation media. There-
after, BSA and HySoy supplemented cultures showed 
34% and 39% increase in cell yields respectively by day 3 
and achieved cell densities of  2.16 × 106 and 2.32 × 106 
cells/mL on day 10, as compared to 1.65 × 106 and 1.44 
× 106 cells/mL in the control cultures respectively (Figure 
5A and B). At the end of  the culture, addition of  BSA 
and HySoy resulted in a rise in cell yield by 23% and 19% 
respectively as compared to the controls. 
qRT-PCR analysis show that both supplemented 
cultures and SB control culture displayed similar trends 
of  down regulation of  pluripotent markers (Nanog and 
OCT4) as well as up-regulation of  mesoderm mark-
ers (Mesp 1 and T-bra) (Figure 5C and D). However, 
cultures with supplements showed a significantly higher 
expression of  cardiac progenitor gene Nkx 2.5 as well as 
a higher general trend of  late cardiomyocyte gene MHC 
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expression during the later stages as compared to SB con-
trol cultures (Figure 5C and D). In summary, the addition 
of  supplements, BSA and HySoy, not only enhanced 
cardiomyogenesis via improvement in cell yield, but also 
increased the expressions of  both Nkx 2.5 and MHC.
Robustness of SupSB medium: Increased 
cardiomyogenesis with other pluripotent cell lines
In order to demonstrate the universality and robustness 
of  SupSB media for increased cardiomyogenesis induc-
tion efficiency, we cultured two additional cell lines, H1 
hESC and Siu1-hiPSC. These cells were differentiated 
in SupSB medium for 16 d and tested for cell yields and 
cardiac marker expression, with cells differentiated in 
SB medium used as controls. Results show that cultur-
ing cells in SupSB medium led to increased cell density 
from 1.10 × 106 to 3.12 × 106 cells/mL for H1 and from 
0.67 × 106 to 1.22 × 106 cells/mL for Siu1-hiPSC as 
compared to SB media (Table 3). Moreover, significantly 
higher expression of  the cardiac specific marker MHC 
was observed in cultures with SupSB medium (Table 3). 
H1 cultures differentiated in SupSB medium showed a 
significant increase in normalized cardiomyocyte yield 
of  15-fold over the control, while Siu1-hiPSC showed a 
9-fold increase (Table 3). Cardiomyocyte yield per hESC 
seeded was 0.59 cardiomyocyte/hESC for H1 cultures 
and 0.04 cardiomyocyte/hESC for Siu1-hiPSC cultures. 
Another factor that can influence the yield of  car-
diomyocyte differentiation is the age or passage number 
of  the cells. As such, HES-3 cells at early (P12 to P13) 
and late (P21 to P39) passages were differentiated using 
SupSB medium and cardiomyocyte yields were measured 
at day 16. Results in Figure 6 show that cells from early 
or late passage showed similar cardiomyocyte yields.
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Figure 5  Cell growth and gene expression kinetics of HES-3 cells grown in cultures with and without supplements. Cell densities at multiple times points 
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93 July 26, 2013|Volume 5|Issue 3|WJSC|www.wjgnet.com
Characterization of cardiomyocytes obtained from 
SupSB differentiation medium
HES-3, H1 and Siu1-hiPSC cells differentiated in SupSB 
medium all showed increases in cell yield, expression of  
cardiac markers and cardiomyocyte yields (Table 3). The 
increase in cell yield can be attributed to better metabolic 
conditions manifested by an increase of  20%-30% in 
cell viability over the control and an increased expression 
of  proliferation marker Ki-67[28]. Specifically, at day 2 of  
differentiation, 12% increase in Ki-67 expression was ob-
served in cultures differentiated in SupSB medium com-
pared to SB medium. By day 4 onward, Ki-67 expression 
was similar in both cultures (data not shown).The percent-
age of  beating aggregates in cultures with SupSB medium 
was also higher than that in SB medium (Figure 7). 
Cardiomyocytes differentiated in SupSB medium 
were also characterized via immunostaining of  cardiac 
proteins. 16 d old EBs were harvested, mechanically dis-
sociated, and plated on 0.1% gelatin-coated 24-well plates 
before staining with a set of  antibodies against cardiac-
specific markers (Figure 8A-C). Cells stained positive 
for cytoskeleton structural proteins (SA) and contractile 
functional proteins responsible for motility (MHC, and 
troponin-T)[29].Electrophysiological study via whole-cell 
patch-clamping was performed. Action potential dura-
tions at 90% and 50% repolarization levels as well as 
maximal diastolic potential were recorded using HES-3 
cells differentiated for 23 d. Cells differentiated in both 
SB and SupSB medium gave similar results. All the three 
major phenotypes of  cardiomyocytes: nodal-, atrial- and 
ventricular-like were obtained (Figure 8D). The APD and 
maximal diastolic potential of  the cardiomyocytes were 
similar for cells cultured in both SB and SupSB media 
(Figure 8E-G) and are comparable to those of  the con-
trol hESC cell line H7 (data not shown). 
Furthermore, a normal karyotype was observed in 
20 d old cardiomyocytes differentiated in SupSB medium 
(Figure 9).
DISCUSSION
In this paper, we have demonstrated that the media 
supplements, HySoy and BSA, can improve the differ-
entiation efficiency of  hESCs into cardiomyocytes when 
added to SB media containing the p38 MAP kinase inhib-
itor, SB203580. In particular, when combined at optimal 
concentrations (0.25%HySoy and 0.50%BSA), the car-
diomyocyte yield is enhanced by 2.6-fold compared to the 
SB medium without supplements for the HES-3 cell line. 
This increase is due to the improvement in cell growth, 
as well as differentiation efficiency. Cell lines such as, H1 
and Siu1-hiPSC, which initially did not differentiate ef-
ficiently to cardiomyocytes in the SB media, showed sig-
nificant improvements in yields of  cardiomyocyte/hESC 
or cardiomyocyte/hiPSC (15- and 9-fold respectively) 
when these supplements were added. The variability in 
cardiomyocyte differentiation yields between cell lines is 
not surprising and it likely reflects genetic and epigenetic 
differences between pluripotent stem cell lines[30-32] that 
influences their cardiac differentiation efficiencies[14,15,33]. 
Moreover, the level of  differentiation obtained in SupSB 
medium was consistent and not affected by cell age (pas-
sages 12 to 39). We have observed varying ratios of  ex-
pression levels for MHC and SA, ranging from 1:1 to 1:16 
(MHC: SA) (Table 3). These differences can be attributed 
to the stages in the differentiation process which the cells 
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Table 3  Summary of results: Robustness of SupSB vs  SB media for cell lines HES-3, H1 and Siu1-human induced pluripotent stem cells
        Conditions Cell expansion Differentiation efficiency CM yield
Cell type Medium Cell yield (106 cells/mL) Cell expansion fold Sarcomeric actinin MHC Cardiomyocyte/hESC
HES-3 SupSB 2.27 ± 0.58 1.65 ± 0.47 14.70% ± 6.30% 13.59% ± 3.40%   0.21 ± 0.08
SB 1.66 ± 0.48 1.25 ± 0.36   9.25% ± 6.19%   6.17% ± 2.95%   0.07 ± 0.03
H1 SupSB 3.14 ± 0.24 2.35 ± 0.18 26.70% ± 2.09% 25.20% ± 5.41%   0.59 ± 0.01
SB 1.10 ± 0.19 0.82 ± 0.14 20.23% ± 1.87%   4.76% ± 1.62%   0.04 ± 0.01
Siu1-hiPSC SupSB 1.22 ± 0.15 0.92 ± 0.11 20.76% ± 4.74%   2.11% ± 0.73%   0.04 ± 0.04
SB 0.67 ± 0.26 0.51 ± 0.20 16.90% ± 1.95%   1.01% ± 0.20% 0.004 ± 0.001
MHC: Myosin heavy chain. Cultures with SupSB medium were compared against SB medium for cell expansion and differentiation efficiency at the end 
of culture (day 16). The results were summarized by calculating the cardiomyocyte yield [cardiomyocytes (CM) yield] which takes into account the ratio of 
cardiomyocytes at day 16 compared to the initial human embryonic stem cells (hESC) seeded (n = 3 to 9).
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Figure 6  Robustness of SupSB medium over different cell ages (passage). 
HES-3 cells from different passages (P12 to P39) were differentiated using the 
supplements, Soy hydrolysate (HySoy) and bovine serum albumin (BSA). The 
passages were divided into two groups: Early passage (P12 to P13) and Late 
Passage (P21 to P39). There is no significant difference in cardiomyocyte yield 
at different passages. Student t-test and one-way ANOVA test were used to 
calculate the statistical significance of the data.
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Figure 7  Phase contrast microscopy of cardiomyocytes obtained from differentiation of HES-3 cells. Pictures of aggregates formed from human embryonic stem 
cells differentiated in SB media (A) and SupSB media (B) were taken after 16 d. Beating areas are indicated by red circles. Total number of beating aggregates was higher 
in cultures differentiated in SupSB medium(about 80% of total aggregates) compared to in SB medium (about 60% of total aggregates). Scale bar = 200 µm. 
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are at. SA is expressed earlier than MHC during cardiac 
differentiation[34]. Cultures expressing a higher ratio of  
SA to MHC (16:1) indicate an earlier stage of  differentia-
tion in comparison to cultures with lower ratios.
The results from qRT-PCR analysis showed no accel-
eration in the differentiation process when cells cultured 
with supplements (BSA and HySoy) were compared to 
SB media, with expression of  pluripotent and mesoderm 
markers showing similar trends. However, there was a 
significantly higher expression of  Nkx 2.5, indicating 
a higher population of  cardiac progenitor cells in the 
cultures with supplements. MHC expression showed a 
higher general trend, but not a significant increase, when 
comparing cells cultured with individual supplements to 
those cultured in SB media only. However, when the sup-
plements were combined, their additive effect produced 
a significantly higher expression of  MHC, indicating that 
SupSB media improves the differentiation efficiency of  
cardiomyocytes.
Albumin, as a major serum protein with a typical con-
centration of  50 mg/mL in blood, accounts for approxi-
mately 60% of  the total protein in mammals[35]. Although 
there is such an abundance of  albumin, its physiological 
actions and molecular mechanisms are not fully under-
stood[36,37]. The main functions of  albumin have been sum-
marized to include (1) maintenance of  blood oncotic pres-
sure and pH; (2) binding and transport of  physiologically 
important nutrients, including lipids, metal ions, amino acids 
and other factors; and (3) antioxidant functions but mainly 
from the perspective of  its role in blood circulation[35]. 
Protein hydrolysates are known as a potential source 
of  metabolizable materials including amino acids, oli-
gopeptides, iron salts, lipids and trace elements. Their 
beneficial effects to the growth of  animal cell culture 
have been known for more than two decades[38] and are 
generally thought to act as a concentrated balanced nutri-
ent mixture that may partly or fully replace serum[39,40]. 
In recent years suppliers have improved their production 
processes to generate more consistent products with less 
batch-to-batch variability for the biopharma industry[41]. 
Multiple reports have shown the effect of  protein hydro-
lysates on growth in a variety of  cell lines including both 
animal and rodent cells[40,42]. This study further validates 
HySoy as a suitable supplement for cardiomyocyte differ-
entiation. 
The increase in cardiomyocyte efficiency was attrib-
uted to two reasons: (1) increased cell growth; and (2) 
increased differentiation efficiency, probably due to the 
improved metabolic state of  the cells. Both BSA and Hy-
Soy have been repeatedly reported to increase cell densi-
ties in various different cell lines, and thus, the increase in 
cell growth observed during cardiomyocyte differentiation 
is not surprising. BSA and HySoy are also more defined in 
comparison to Fetal Bovine Serum, which is widely used 
in current EB and monolayer differentiation protocols[4,10]. 
We assume that the addition of  albumin and HySoy to the 
differentiation medium improves cardiomyocyte cell yields 
and viability by their antioxidant activity, conferring need-
ed metabolized nutrients and the ability to transport nutri-
ents (e.g., lipids) to the cells. Previously it has been shown 
that insulin inhibits the process of  cardiomyogenesis, 
therefore it was removed from the SB media[43]. BSA and 
HySoy supplements were able to restore the proliferative 
capacity of  cardiomyocytes in this insulin-free SupSB me-
dia. Moreover, it was reported that BSA can also help in 
the transport of  small molecules such as the p38 MAPK 
inhibitor to the cells[35]. Maturation of  cardiomyocytes into 
ventricular, atrial and nodal phenotypes occurred within 
16 d of  differentiation as shown by the electrophysiology 
characterization. Ventricular phenotype maturation was 
much faster in comparison to other works which indicated 
a time frame of  60 d[8].
Currently, there are multiple companies offering com-
plete medium for hESC cardiac differentiation, these media 
use expensive ingredients and thus they are considerably 
more expensive then SupSB media. This work is the first 
step in developing an inexpensive and efficient cardiomyo-
cyte differentiation protocol that can be used by commercial 
companies to produce cardiomyocytes. To the best of  our 
knowledge, this is the first report of  the benefits of  BSA 
and HySoy on improving cardiomyogenesis of  pluripotent 
human stem cells. Future works into cardiomyocyte purifi-
cation and increase cardiomyocyte yield is needed.
In conclusion, we have created a simple, robust and 
cost effective media that significantly improves cardio-
myocyte differentiation over many passages for multiple 
pluripotent cell lines that will be useful for research and 
cell therapy applications.
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and accounts for more than 800000 deaths per year on average in the United 
States alone. After an episode of major cardiac insult (such as a myocardial in-
farction), the heart can lose up to 2 billion cardiomyocytes. Being an organ that 
cannot auto-regenerate, progressive heart failure develops. Cardiomyocyte cell 
therapy can thus be a potential cure for heart failure after myocardial infarction, 
and it is suggested that at least one billion cardiomyocytes will be required per 
patient for such treatment
Research frontiers
Human embryonic stem cells (hESCs) present an attractive cell source for gen-
erating large amounts of cardiomyocytes, due to their pluripotency and ability to 
proliferate for multiple passages. As such, several studies have reported tech-
niques to efficiently differentiate hESCs to cardiomyocytes via growth factors 
and small molecule inhibitors. Specifically, a protocol based on the inhibition of 
p38 MAPK with small molecules displayed the ability to be scaled up in a cost 
efficient manner. However, low cell yield and viability were inherent to this pro-
tocol, reducing the output of cardiomyocytes.
Innovations and breakthroughs
Soy hydrolysate (HySoy) and bovine serum albumin (BSA) were found to im-
prove cell viability during cardiomyogenesis of human embryonic and induced 
pluripotent stem cells in serum free medium. The addition of both supplements 
leads to an increase in cell viability, cell yield and cardiac marker expression 
during cardiomyocyte differentiation, translating to an overall increase in cardio-
myocyte yield (2.6 fold increase over non supplemented medium).
Applications
Authors have created a simple, robust and cost effective serum free medium 
(SupSB media) that significantly improves cardiomyocyte differentiation of 
human pluripotent stem cell in suspended embryoid bodies culture. The new 
medium can be used for research and cell therapy applications using human 
embryonic and induced pluripotent cultures.
Terminology
p38 MAPK are a class of protein kinases involved in pathways that deal with 
differentiation, apoptosis and autophagy. p38 MAPK was inhibited with small 
molecule, SB203580.
Peer review
The authors have carried out an interesting study in which they developed an 
inexpensive and efficient cardiomyocyte differentiation protocol that can be 
used to produce cardiomyocytes. They demonstrated the benefits of BSA and 
HySoy on improving cardiomyogenesis of pluripotent human stem cells.
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